Home › Trials › NCT04641143

Evaluating the effectiveness of troriluzole for treating obsessive-compulsive disorder

A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Phase 3 Interventional Biohaven Pharmaceuticals, Inc. · NCT04641143

This study is testing if adding a new medication called troriluzole can help people with obsessive-compulsive disorder who haven't had enough improvement from their current treatments.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment700 (estimated)
Ages18 Years to 65 Years
SexAll
SponsorBiohaven Pharmaceuticals, Inc. Industry-sponsored
Locations96 sites (Chandler, Arizona and 95 other locations)
Trial IDNCT04641143 on ClinicalTrials.gov

What this trial studies

This study aims to assess the efficacy and safety of troriluzole as an additional treatment for patients with obsessive-compulsive disorder (OCD) who have not responded adequately to standard medications. Participants will receive either troriluzole or a placebo while their symptoms are monitored over the course of the trial. The study will include individuals diagnosed with OCD for at least one year and who have shown minimal improvement with current treatments. The goal is to determine if adding troriluzole can provide better outcomes for these patients.

Who should consider this trial

Good fit: Ideal candidates are adults diagnosed with obsessive-compulsive disorder for at least one year and who have not experienced sufficient relief from standard medications.

Not a fit: Patients who have not been diagnosed with obsessive-compulsive disorder or those who have not tried standard treatments may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the quality of life for patients suffering from OCD who have not responded to existing therapies.

How similar studies have performed: While there have been studies on various treatments for OCD, the specific use of troriluzole as an adjunctive therapy is relatively novel and has not been extensively tested in this context.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Primary diagnosis of obsessive-compulsive disorder (OCD) as per Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition as confirmed by the MINI at Screening; The duration of the subject's illness must be ≥ 1 year
2. An inadequate response to current Standard of Care medication defined as selective serotonin reuptake inhibitor (excluding fluvoxamine) or clomipramine treatment at an adequate and stable dose for at least 8 weeks prior to screening and at least 12 weeks at baseline (adequate dose defined by USPI labeling); an inadequate response as defined per the MGH-TRQ-OCD, there has been minimal or no meaningful clinical benefit as perceived by the subject
3. Determined by the investigator to be medically stable at baseline/randomization as assessed by medical history, physical examination, laboratory test results, and electrocardiogram testing. Subjects must be physically able and expected to complete the trial as designed

Exclusion Criteria:

1. Subjects with a history of more than two (2) previous failed or inadequate treatment classes given for an adequate duration at an adequate dose as defined by the MGH-TRQ-OCD.
2. Current or prior history of: bipolar I or II disorder, schizophrenia or other psychotic disorders, schizoaffective disorder, autism or autistic spectrum disorders, borderline personality disorder, antisocial personality disorder, Tourette's disorder, body dysmorphic disorder, hoarding disorder; or psychosurgery, Deep Brain Stimulation (DBS) or Electroconvulsive Therapy (ECT); or general medical condition that may confound safety and/or efficacy results
3. Previous treatment in a study with troriluzole

Where this trial is running

Chandler, Arizona and 95 other locations

+46 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Obsessive-Compulsive DisorderOCD
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.